Tenofovir alafenamide stops HBV transmission from mother to infant
02 Nov 2020
bởiJairia Dela Cruz
In highly viraemic mothers, initiating treatment with tenofovir alafenamide fumarate (TAF) at the 13th gestational week or later in pregnancy puts a lid on hepatitis B virus (HBV) and prevents vertical transmission when infants receive standard immunoprophylaxis, as shown in a study.